Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
The KRAS gene is a member of the RAS gene family, encoding a small GTPase protein that plays a critical role in cellular signal transduction pathways. It regulates key cellular processes such as growth, differentiation, and survival. Under normal conditions, the KRAS protein toggles between an active state (bound to GTP) and an inactive state (bound to GDP), precisely controlling downstream signaling pathways to maintain normal cellular functions. However, mutations in the KRAS gene can cause the KRAS protein to remain constitutively active, leading to abnormal activation of downstream signaling pathways and disrupting normal cellular growth regulation mechanisms.
KRAS gene mutations are closely associated with the development of various malignant tumors, including pancreatic cancer, colorectal cancer, and lung cancer. In pancreatic cancer, KRAS mutations occur at an extremely high frequency and are a significant factor contributing to its aggressive nature and poor prognosis. In colorectal cancer, the KRAS mutation status is critical for determining treatment options and assessing patient prognosis, as it influences the efficacy of targeted therapies. Similarly, in non-small cell lung cancer (NSCLC), KRAS mutations are a key driver of disease progression and treatment response.
Advances in KRAS research have led to progress in the development of inhibitors targeting KRAS mutations. For example, covalent inhibitors directly target the KRAS protein by binding to specific sites on the mutated protein, disrupting its function and inhibiting tumor cell growth. Additionally, indirect inhibitors target downstream signaling molecules such as MEK and ERK, blocking abnormally activated pathways to achieve anti-tumor effects. Sotorasib, Adagrasib, Fulzerasib (Dabote) and Garsorasib (Anfangning) are approved KRAS-G12C inhibitors for the treatment of patients. These inhibitors offer new hope for treating KRAS-mutated cancers, but there is an urgent need for reliable cell models to facilitate drug screening and mechanistic studies.
BaF3-KRAS stable cell lines are used to evaluate the efficacy of various KRAS inhibitors. By observing the effects of different drugs on cell growth inhibition and apoptosis induction, researchers can quickly identify promising drug candidates, providing a foundation for preclinical and clinical studies. Creative Biogene has developed a series of BaF3-KRAS stable cell line products allowing a one-stop solution for KRAS-targeted drug development. From cell line construction to preservation, every step follows strict standard operating procedures and quality testing protocols. We use advanced molecular biology techniques, such as gene sequencing and expression analysis, to ensure the highest quality of our BaF3-KRAS stable cell lines. By choosing our BaF3-KRAS stable cell lines, you gain access to a reliable, high-quality tool that accelerates your KRAS-related research and drug development. Contact us today to learn more about how we can support your scientific endeavors!
1) Genetic Stability: Our BaF3-KRAS stable cell lines undergo rigorous screening and validation, ensuring consistent KRAS gene expression and reducing experimental variability.
2) Cell Viability: High cell viability ensuring reliable and reproducible experimental results.
3) Gene Detection: Gene sequencing confirms the accuracy of KRAS mutation sites, with no additional genetic variations that could affect cell function.
4) Gene Expression Analysis: qPCR analysis shows stable and high expression of KRAS in our BaF3-KRAS stable cell lines.
5) Ease of Culturing and Handling: BaF3 cells grow rapidly and are adaptable to standard laboratory conditions, making them ideal for large-scale culturing and high-throughput screening.
6) These cell lines mimic the biological characteristics of KRAS-mutated tumor cells, providing a reliable in vitro model for predicting in vivo drug efficacy and improving drug development success rates.
7) All of our cell lines are guaranteed mycoplasma free.
8) Comprehensive Product Line: We have a list of BaF3-KRAS stable cell lines with various KRAS mutation types that are available in stock, and we also provide custom generation services to meet diverse research needs.
9) Expert Technical Support Team: Our team of experts in cell and molecular biology provides professional guidance on cell culturing, experimental design, and data analysis, ensuring smooth progress in your research.
1. qPCR Analysis of Gene Expression Level
2. Inhibitor IC50 Assay
3. Mycoplasma Detection
| MycoAlert Mycoplasma Detection Data | ||||
| Luminescence | A Value | B Value | B/A ratio | Result |
| Negative Control | 2168 | 575 | 0.26522 | / |
| Positive Control | 20232 | 1249308 | 61.74911 | / |
| BaF3-Human-KRAS-G12C-H95Q | 23615 | 11212 | 0.47478 | Negative/- |
| BaF3-Human-KRAS-G12C-Q99L | 27353 | 10768 | 0.39367 | Negative/- |
| Luminescence | A Value | B Value | B/A ratio | Result |
| Negative Control | 2316 | 593 | 0.25604 | / |
| Positive Control | 19479 | 1152942 | 59.18897 | / |
| BaF3-Human-KRAS-G12R | 24088 | 9976 | 0.41415 | Negative/- |
| Luminescence | A Value | B Value | B/A ratio | Result |
| Negative Control | 1326 | 510 | 0.38462 | / |
| Positive Control | 17158 | 1104715 | 64.38484 | / |
| BaF3-Human-KRAS-G12V | 19282 | 9498 | 0.49258 | Negative/- |
4. Cell Morphology
 |  |
| BaF3-Human-KRAS-G12C-H95Q (4X) | BaF3-Human-KRAS-G12C-H95Q (10X) |
 |  |
| BaF3-Human-KRAS-G12C-Q99L (4X) | BaF3-Human-KRAS-G12C-Q99L (10X) |
 |  |
| BaF3-Human-KRAS-G12R (4X) | BaF3-Human-KRAS-G12R (10X) |
 |  |
| BaF3-Human-KRAS-G12V (4X) | BaF3-Human-KRAS-G12V (10X) |
Copyright © Creative Biogene. All rights reserved.